Eisai continues with sepsis trial
This article was originally published in Pharmaceutical Approvals Monthly
An independent data monitoring committee gives Eisai the green light to complete enrollment for its Phase III ACCESS trial of Eritoran (tetrasodium) to treat severe sepsis. As part of a planned interim analysis, the board evaluated the efficacy and safety of the first 1,500 patients in the placebo-controlled trial, and recommended enrollment continue to the 2,000-patient goal after finding no safety concerns. The ACCESS trial targets a population with severe sepsis that has a moderate to high risk of mortality as determined by baseline APACHE II scores from 21 to 37 - APACHE II is a severity of illness scoring system commonly used in sepsis research. Though sepsis has proven to be a difficult development path (Lilly's Xigris is the only approved treatment), the go-ahead is a good sign for Eisai, which is counting on future Eritoran sales to offset the Aricept patent loss (1PharmAsia News, March 5, 2010)
You may also be interested in...
Eisai expects product launches and increased sales of existing drugs to help it survive the loss of U.S. patent protection for its best-selling Aricept (donepezil) Alzheimer's disease drug later this year
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.
Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.